We’re moving!📍 It’s official: effective November 1, Altimmune will call Morristown, New Jersey, home. We’re excited to become part of the Morristown community as we continue focusing our work developing an investigational therapy for the treatment of serious liver diseases.

Altimmune will be attending #AASLD26 next month! We look forward to connecting with the liver disease community and presenting data on our investigational treatment. Find the full list of Altimmune presentations: ir.altimmune.com/news-releas…

Altimmune is joining @liverUSA in marking National Liver Awareness Month this October, with a focus on raising awareness about serious #LiverDisease. Learn more about liver disease and the importance of education and awareness: liverfoundation.org/resource…

Altimmune is advancing programs in #MASH, #ALD and #AUD. Learn more about our approach to serious liver disease: altimmune.com/pipeline/

Altimmune will be participating in a virtual fireside chat at the Stifel Cardiometabolic Forum. ir.altimmune.com/news-releas…

Altimmune will be participating in the upcoming @WellsFargo Healthcare Conference. ir.altimmune.com/news-releas…

Research progress takes sustained effort. At Altimmune, cross-functional teams are working together to advance science in #liverdisease that has the potential to significantly improve patients’ lives. Learn more about our pipeline: altimmune.com/pipeline/

Millions of people are living with Alcohol-associated #LiverDisease (ALD), a serious and progressive condition with no approved treatment options. Altimmune is committed to advancing research to help address the significant unmet need in ALD.

Today, Altimmune announced Q2 2026 financial results. Learn more: ir.altimmune.com/news-releas…

We are excited to announce initiation of our PERFORMA Phase 3 trial in MASH, reflecting our continued commitment to advancing research for people living with serious #LiverDiseases. Learn more: ir.altimmune.com/news-releas…

We're excited to announce positive topline results from our Phase 2 RECLAIM study evaluating our investigational balanced 1:1 glucagon/GLP-1 dual agonist in alcohol use disorder (AUD). Learn more about the results and next steps: ir.altimmune.com/news-releas…

Despite some approved treatments, there is a need for new #MASH treatments that meet the evolving needs of patients. Altimmune recognizes this need and is committed to working to develop new and innovative treatment approaches for patients.

Alcohol use disorder (#AUD) and alcohol-associated #LiverDisease (ALD) are closely connected but are two different conditions. At Altimmune, we are committed to advancing research that addresses both the disease and the underlying drivers.

Alcohol use can negatively impact liver health. At Altimmune, we’re focused on advancing research to better understand and address the intersection of alcohol use disorder and liver disease. Learn more about our pipeline: altimmune.com/pipeline #AUD

We’re proud to be a platinum sponsor of SOLAR Conference. Altimmune will present three abstracts, including one oral presentation and two posters. We look forward to meeting with experts to discuss the breakthroughs shaping the future of #LiverDisease.

In the U.S., 6 million adults are diagnosed with Alcohol‑associated liver disease (#ALD), yet there are currently no approved therapies. We are committed to addressing this critical gap in care and the need to advance research in #LiverDisease.

This Global #FattyLiverDay, Altimmune is proud to be a part of the community that is working to advance innovation for patients with #MASH and serious liver disease.

The Goldman Sachs 47th Annual Global Healthcare Conference is underway in Miami. Join us for a fireside chat on June 10th at 8 am ET: bit.ly/4e0FhqI

Excited to be on the ground at the @Jefferies Healthcare Conference in New York City alongside fellow leaders across biopharma. Join us on June 4th at 12:50 pm ET for a fireside chat with Altimmune leadership: bit.ly/4xaF9hf #Biotech #LiverDisease

At #EASL26, we shared new Phase 2b data in metabolic dysfunction‑associated steatohepatitis (#MASH) and more about our work in #LiverDisease.